Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

caracemide

An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase. In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Chemical structure:acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)
N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea
IND number:22624
NSC code:253272
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search